Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies. The global immunoglobulin was valued at $8,374 million in 2016, and is projected to reach $13,619 million by 2023, registering a CAGR of 7.3% from 2017 to 2023. Research Beam Model: Research Beam Product ID: 1999826 5370 USD New
Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations]) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations]) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : September  2017
  • Pages : 220
 
 

Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies. The global immunoglobulin was valued at $8,374 million in 2016, and is projected to reach $13,619 million by 2023, registering a CAGR of 7.3% from 2017 to 2023.

The report segments the global immunoglobulin market based on application, product type, mode of delivery, and concentration. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Hypogammaglobulinemia and CIDP held dominant market shares in 2016 due to the large patient population and unavailability of effective alternatives to immunoglobulin treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. Intravenous mode of delivery is further categorized into 5%, 10%, and other concentration. Subcutaneous mode of delivery is further classified into 16.5%, 20%, and other concentration.

Immunoglobulin market is driven by the increase in prevalence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia, and rise in use of immunoglobulins to treat Guillain‐Barre syndrome, inflammatory myopathies, specific antibody deficiency, and others. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin. Increase in geriatric population and hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) are the other key factors that contribute to the market growth. In addition, the market is restrained by the stringent government regulations, high cost of therapy, and high risk of side effects associated with the use of immunoglobulin.

KEY MARKET BENEFITS

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to products type, application, mode of delivery, and geography.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Baxter international Inc.
  • CSL Ltd.
  • Grifols S.A.
  • Octapharma AG
  • Kedrion Biopharma Inc.
  • LFB group
  • Biotest AG
  • China Biologics Products, Inc.
  • BDI Pharma Inc.
  • Bayer Healthcare

KEY MARKET SEGMENTS

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain–Barré Syndrome
  • Others

By Product

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Mode of Delivery

  • Intravenous
  • 5% Concentration
  • 10% Concentration
  • Others
  • Subcutaneous
  • 16.5% Concentration
  • 20% Concentration
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Austria
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Argentina
    • Saudi Arabia
    • Rest of LAMEA

The other players of the catheters market include (companies not profiled in the report):

  • Hualan Biological Engineering Inc.
  • Omrix Biopharmaceuticals Ltd.
  • Behring GmbH
  • Shanghai RAAS Blood Products Co., Ltd.
  • Option Care Enterprises, Inc.
  • ADMA Biologics, Inc.
  • BioScrip, Inc.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IMMUNOGLOBULIN

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. SIDE EFFECTS OF IMMUNOGLOBULIN TREATMENT
3.5. KEY FINDINGS

3.5.1. Top factors impacting
3.5.2. Top investment pockets

3.6. PORTERS FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support activities

3.8. MARKET SHARE ANALYSIS, 2016
3.9. PRODUCT SCENARIO IN IMMUNOGLOBULIN MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. U.S.
3.10.2. Europe

3.10.2.1. France
3.10.2.2. Germany
3.10.2.3. Italy

3.10.3. China
3.10.4. Japan
3.10.5. India

3.11. INDICATIONS FOR IMMUNOGLOBULIN

3.11.1. U.S. FDA indications
3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.14. MARKET DYNAMICS

3.14.1. Drivers

3.14.1.1. Rise in prevalence of immunodeficiency diseases
3.14.1.2. Increase in adoption of immunoglobulin
3.14.1.3. Increase in incidence of bleeding disorders
3.14.1.4. Surge in geriatric population

3.14.2. Restraints

3.14.2.1. Stringent government regulations
3.14.2.2. High cost of therapy

3.14.3. Opportunities

3.14.3.1. Opportunities in emerging economies
3.14.3.2. Development of cost-effective therapeutics through large-scale production

CHAPTER 4 IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. PRIMARY IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

CHAPTER 5 IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. OVERVIEW
5.2. IGG

5.2.1. Key market trends
5.2.2. Clinical interpretations

5.3. IGA

5.3.1. Key market trends
5.3.2. Clinical interpretation

5.4. IGM

5.4.1. Key market trends
5.4.2. Clinical interpretation

5.5. IGE

5.5.1. Key market trends
5.5.2. Clinical Interpretation

5.6. IGD

5.6.1. Key market trends
5.6.2. Clinical interpretations

CHAPTER 6 IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. INTRAVENOUS MODE OF DELIVERY

6.2.1. Key market trends
6.2.2. Market size and forecast
6.2.3. 5% concentration

6.2.3.1. Market size and forecast

6.2.4. 10% concentration

6.2.4.1. Market size and forecast

6.2.5. Other concentrations

6.2.5.1. Market size and forecast

6.3. SUBCUTANEOUS MODE OF DELIVERY

6.3.1. Key market trends
6.3.2. Market size and forecast
6.3.3. 16.5% concentration

6.3.3.1. Market size and forecast

6.3.4. 20% concentration

6.3.4.1. Market size and forecast

6.3.5. Other concentrations

6.3.5.1. Market size and forecast

CHAPTER 7 IMMUNOGLOBULIN MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Market size and forecast
7.2.3. North America IVIG market

7.2.3.1. Market size and forecast

7.2.4. North America SCIG market

7.2.4.1. Market size and forecast

7.2.5. U.S.

7.2.5.1. Market size and forecast
7.2.5.2. U.S. IVIG market size and forecast
7.2.5.3. U.S. SCIG market size and forecast

7.2.6. Canada

7.2.6.1. Market size and forecast
7.2.6.2. Canada IVIG market size and forecast
7.2.6.3. Canada SCIG market size and forecast

7.2.7. Mexico

7.2.7.1. Market size and forecast
7.2.7.2. Mexico IVIG market size and forecast
7.2.7.3. Mexico SCIG market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Market size and forecast
7.3.3. Europe IVIG market

7.3.3.1. Market size and forecast

7.3.4. Europe SCIG market

7.3.4.1. Market size and forecast

7.3.5. UK

7.3.5.1. Market size and forecast
7.3.5.2. UK IVIG market size and forecast
7.3.5.3. UK SCIG market size and forecast

7.3.6. France

7.3.6.1. Market size and forecast
7.3.6.2. France IVIG market size and forecast
7.3.6.3. France SCIG market size and forecast

7.3.7. Germany

7.3.7.1. Market size and forecast
7.3.7.2. Germany IVIG market size and forecast
7.3.7.3. Germany SCIG market size and forecast

7.3.8. Italy

7.3.8.1. Market size and forecast
7.3.8.2. Italy IVIG market size and forecast
7.3.8.3. Italy SCIG market size and forecast

7.3.9. Austria

7.3.9.1. Market size and forecast
7.3.9.2. Austria IVIG market size and forecast
7.3.9.3. Austria SCIG market size and forecast

7.3.10. Russia

7.3.10.1. Market size and forecast
7.3.10.2. Russia IVIG market size and forecast
7.3.10.3. Russia SCIG market size and forecast

7.3.11. Rest of Europe

7.3.11.1. Market size and forecast
7.3.11.2. Rest of Europe IVIG market size and forecast
7.3.11.3. Rest of Europe SCIG market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Market size and forecast
7.4.3. Asia-Pacific IVIG market

7.4.3.1. Market size and forecast

7.4.4. Asia-Pacific SCIG market

7.4.4.1. Market size and forecast

7.4.5. Australia

7.4.5.1. Market size and forecast
7.4.5.2. Australia IVIG market size and forecast
7.4.5.3. Australia SCIG market size and forecast

7.4.6. China

7.4.6.1. Market size and forecast
7.4.6.2. China IVIG market size and forecast
7.4.6.3. China SCIG market size and forecast

7.4.7. Japan

7.4.7.1. Market size and forecast
7.4.7.2. Japan IVIG market size and forecast
7.4.7.3. Japan SCIG market size and forecast

7.4.8. India

7.4.8.1. Market size and forecast
7.4.8.2. India IVIG market size and forecast
7.4.8.3. India SCIG market size and forecast

7.4.9. Rest of Asia-Pacific

7.4.9.1. Market size and forecast
7.4.9.2. Rest of Asia-Pacific IVIG market size and forecast
7.4.9.3. Rest of Asia-Pacific SCIG market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Market size and forecast
7.5.3. LAMEA IVIG market

7.5.3.1. Market size and forecast

7.5.4. LAMEA SCIG market

7.5.4.1. Market size and forecast

7.5.5. Brazil

7.5.5.1. Market size and forecast
7.5.5.2. Brazil IVIG market size and forecast
7.5.5.3. Brazil SCIG market size and forecast

7.5.6. Argentina

7.5.6.1. Market size and forecast
7.5.6.2. Argentina IVIG market size and forecast
7.5.6.3. Argentina SCIG market size and forecast

7.5.7. Turkey

7.5.7.1. Market size and forecast
7.5.7.2. Turkey IVIG market size and forecast
7.5.7.3. Turkey SCIG market size and forecast

7.5.8. Saudi Arabia

7.5.8.1. Market size and forecast
7.5.8.2. Saudi Arabia IVIG market size and forecast
7.5.8.3. Saudi Arabia SCIG market size and forecast

7.5.9. Rest of LAMEA

7.5.9.1. Market size and forecast
7.5.9.2. Rest of LAMEA IVIG market size and forecast
7.5.9.3. Rest of LAMEA SCIG market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. BAXTER INTERNATIONAL INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. CSL LTD.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments

8.3. GRIFOLS S.A.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. OCTAPHARMA AG

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments

8.5. KEDRION BIOPHARMA INC.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. LFB GROUP

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Key strategic moves and developments

8.7. BIOTEST AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. CHINA BIOLOGICS PRODUCTS, INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. BDI PHARMA INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. BAYER HEALTHCARE

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS
TABLE 2. BASELINE IMMUNOGLOBULIN YEARLY COSTS (2009)
TABLE 3. U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN
TABLE 4. EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN
TABLE 5. IGG SUBCLASS
TABLE 6. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 7. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 8. CLINICAL TRIALS FOR IMMUNOGLOBULIN (2015-2016)
TABLE 9. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2016-2023 (KILOGRAM)
TABLE 11. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 12. GLOBAL IMMUNOGLOBULIN MARKET FOR HYPOGAMMAGLOBULINEMIA, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 13. GLOBAL IMMUNOGLOBULIN MARKET FOR CIDP, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 14. PRINCIPLE OF IMMUNOGLOBULIN THERAPY IN IMMUNODEFICIENCY
TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 16. GLOBAL IMMUNOGLOBULIN MARKET FOR MYASTHENIA GRAVIS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 17. GLOBAL IMMUNOGLOBULIN MARKET FOR MMN, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 18. ITP TREATMENT OPTIONS
TABLE 19. GLOBAL IMMUNOGLOBULIN MARKET FOR PRIMARY ITP, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 20. GLOBAL IMMUNOGLOBULIN MARKET FOR INFLAMMATORY MYOPATHY, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 21. GLOBAL IMMUNOGLOBULIN MARKET FOR SAD, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 22. GLOBAL IMMUNOGLOBULIN MARKET FOR GBS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 23. GLOBAL IMMUNOGLOBULIN MARKET FOR OTHERS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 24. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2016-2023 ($MILLION)
TABLE 25. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2016-2023 (KILOGRAM)
TABLE 26. GLOBAL IMMUNOGLOBULIN MARKET FOR INTRAVENOUS MODE OF DELIVERY, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 27. GLOBAL IVIG MARKET FOR 5% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 28. GLOBAL IVIG MARKET FOR 10% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 29. GLOBAL IVIG MARKET FOR OTHER CONCENTRATIONS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 30. GLOBAL SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 31. GLOBAL SCIG MARKET FOR 16.5% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 32. GLOBAL SCIG MARKET FOR 20% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 33. GLOBAL SCIG MARKET FOR OTHER CONCENTRATIONS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 34. IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 35. IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, 2016-2023 (KILOGRAM)
TABLE 36. NORTH AMERICA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 37. NORTH AMERICA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 38. NORTH AMERICA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 39. U.S. IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 40. U.S. IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 41. U.S. SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 42. CANADA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 43. CANADA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 44. CANADA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 45. MEXICO IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 46. MEXICO IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 47. MEXICO SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 48. EUROPE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 49. EUROPE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 50. EUROPE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 51. UK IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 52. UK IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 53. UK SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 54. FRANCE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 55. FRANCE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 56. FRANCE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 57. GERMANY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 58. GERMANY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 59. GERMANY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 60. ITALY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 61. ITALY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 62. ITALY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 63. AUSTRIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 64. AUSTRIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 65. AUSTRIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 66. RUSSIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 67. RUSSIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 68. RUSSIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 69. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 70. REST OF EUROPE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 71. REST OF EUROPE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 72. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 73. ASIA-PACIFIC IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 74. ASIA-PACIFIC SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 75. AUSTRALIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 76. AUSTRALIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 77. AUSTRALIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 78. CHINA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 79. CHINA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 80. CHINA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 81. JAPAN IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 82. JAPAN IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 83. JAPAN SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 84. INDIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 85. INDIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 86. INDIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 87. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 88. REST OF ASIA-PACIFIC IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 89. REST OF ASIA-PACIFIC SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 90. LAMEA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 91. LAMEA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 92. LAMEA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 93. BRAZIL IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 94. BRAZIL IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 95. BRAZIL SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 96. ARGENTINA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 97. ARGENTINA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 98. ARGENTINA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 99. TURKEY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 100. TURKEY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 101. TURKEY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 102. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 103. SAUDI ARABIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 104. SAUDI ARABIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 105. REST OF LAMEA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 106. REST OF LAMEA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 107. REST OF LAMEA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 108. BAXTER: COMPANY SNAPSHOT
TABLE 109. BAXTER: OPERATING SEGMENTS
TABLE 110. BAXTER: PRODUCT PORTFOLIO
TABLE 111. CSL: COMPANY SNAPSHOT
TABLE 112. CSL: OPERATING SEGMENTS
TABLE 113. GRIFOLS: COMPANY SNAPSHOT
TABLE 114. GRIFOLS: OPERATING SEGMENTS
TABLE 115. GRIFOLS: PRODUCT PORTFOLIO
TABLE 116. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 117. OCTAPHARMA: OPERATING SEGMENTS
TABLE 118. KEDRION: COMPANY SNAPSHOT
TABLE 119. KEDRION: OPERATING SEGMENTS
TABLE 120. KEDRION: PRODUCT PORTFOLIO
TABLE 121. LFB: COMPANY SNAPSHOT
TABLE 122. LFB: OPERATING SEGMENTS
TABLE 123. BIOTEST: COMPANY SNAPSHOT
TABLE 124. BIOTEST: OPERATING SEGMENTS
TABLE 125. BIOTEST: PRODUCT PORTFOLIO
TABLE 126. CHINA BIOLOGICS PRODUCTS: COMPANY SNAPSHOT
TABLE 127. CHINA BIOLOGICS PRODUCTS: OPERATING SEGMENTS
TABLE 128. CHINA BIOLOGICS PRODUCTS: PRODUCT PORTFOLIO
TABLE 129. BDI: COMPANY SNAPSHOT
TABLE 130. BDI: PRODUCT PORTFOLIO
TABLE 131. BAYER: COMPANY SNAPSHOT
TABLE 132. BAYER: OPERATING SEGMENTS
TABLE 133. BAYER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. MARKET SEGMENTATION
FIGURE 2. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IMMUNOGLOBULIN THERAPY
FIGURE 3. TOP IMPACTING FACTORS, 2016-2023
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. BARGAINING POWER OF BUYERS
FIGURE 6. BARGAINING POWER OF SUPPLIERS
FIGURE 7. THREAT OF NEW ENTRANTS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. COMPETITIVE RIVALRY
FIGURE 10. VALUE CHAIN ANALYSIS
FIGURE 11. MARKET SHARE ANALYSIS, 2016
FIGURE 12. BAXTER: REVENUE, 2014-2016 ($MILLION)
FIGURE 13. BAXTER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 14. CSL: REVENUE, 2014-2016 ($MILLION)
FIGURE 15. CSL: REVENUE BY SEGMENT, 2016 (%)
FIGURE 16. GRIFOLS: REVENUE, 2014-2016 ($MILLION)
FIGURE 17. GRIFOLS: REVENUE SHARE BY PRODUCT TYPE, 2016 (%)
FIGURE 18. GRIFOLS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 19. OCTAPHARMA: REVENUE, 2014-2016 ($MILLION)
FIGURE 20. OCTAPHARMA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. OCTAPHARMA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. KEDRION: REVENUE, 2014-2016 ($MILLION)
FIGURE 23. KEDRION: REVENUE BY SEGMENT, 2016 (%)
FIGURE 24. KEDRION: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 25. LFB: REVENUE, 2014-2016 ($MILLION)
FIGURE 26. LFB: REVENUE SHARE BY GEOGRAPHY, 2015 (%)
FIGURE 27. BIOTEST: REVENUE, 2014-2016 ($MILLION)
FIGURE 28. BIOTEST: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29. BIOTEST: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30. CHINA BIOLOGICS PRODUCTS: REVENUE, 2014-2016 ($MILLION)
FIGURE 31. CHINA BIOLOGICS PRODUCTS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 32. CHINA BIOLOGICS PRODUCTS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 33. BDI: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. BDI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 35. BDI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 36. BAYER: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. BAYER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. BAYER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)